Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 3/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348018 | 1.00 | CACNA1B (0.56) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5361495 | 0.99 | CACNA1B (0.56) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5354454 | 0.99 | CACNA1B (0.56) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5355442 | 0.93 | CACNA1B (0.63) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5354620 | 0.93 | CACNA1B (0.63) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5351070 | 0.92 | CACNA1B (0.63) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5345107 | 0.92 | CACNA1B (0.63) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5343490 | 0.91 | CACNA1B (0.65) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5364733 | 0.91 | CACNA1B (0.65) | CACNA1BPPARGPPARAKLK7KLK5 | |
| SCHEMBL5348911 | 0.90 | CACNA1B (0.65) | CACNA1BPPARGPPARAKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | claimed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | claimed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CACNA1B 1/4885PPARG 4040/4885PPARA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.